Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

Bibliography

• Crane R, Gadea B, Littlepage L, et al. Aurora A, meiosis and mitosis. Biol Cell 2004;96:215-29
   PubMed Web of Science ®Google Scholar
• Kollareddy M, Dzubak P, Zheleva D, et al. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:27-33
   PubMed Web of Science ®Google Scholar
• Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96
   PubMed Web of Science ®Google Scholar
• Lee CY, Andersen RO, Cabernard C, et al. Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. Genes Dev 2006;20:3464-74
   PubMed Web of Science ®Google Scholar
• Matsuzaki F. Asymmetric division of Drosophila neural stem cells: a basis for neural diversity. Curr Opin Neurobiol 2000;10:38-44
   PubMedGoogle Scholar
• Guo M, Jan LY, Jan YN. Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron 1996;17:27-41
   PubMed Web of Science ®Google Scholar
• Wirtz-Peitz F, Nishimura T, Knoblich JA. Linking cell cycle to asymmetric division: aurora-A phosphorylates the Par complex to regulate Numb localization. Cell 2008;135:161-73
   PubMed Web of Science ®Google Scholar
• Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54
   PubMed Web of Science ®Google Scholar
• Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63
   PubMed Web of Science ®Google Scholar
• Kitajima S, Kudo Y, Ogawa I, et al. Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007;2:e944
   PubMed Web of Science ®Google Scholar
• Dar AA, Zaika A, Piazuelo MB, et al. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112:1688-98
   PubMed Web of Science ®Google Scholar
• Vischioni B, Oudejans JJ, Vos W, et al. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5:2905-13
   PubMed Web of Science ®Google Scholar
• Fu J, Bian M, Jiang Q, et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10
   PubMed Web of Science ®Google Scholar
• Dutta-Simmons J, Zhang Y, Gorgun G, et al. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 2009;114:2699-708
   PubMedGoogle Scholar
• Ye D, Garcia-Manero G, Kantarjian HM, et al. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2009;2:2-8
   PubMedGoogle Scholar
• Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008;3:114-22
   PubMedGoogle Scholar
• Agnese V, Bazan V, Fiorentino FP, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18(Suppl 6):vi47-52
   PubMedGoogle Scholar
• Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors – rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
   PubMed Web of Science ®Google Scholar
• Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2011;31:757-93
   PubMed Web of Science ®Google Scholar
• Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18:379-98
   PubMed Web of Science ®Google Scholar
• Coumar MS, Cheung CH, Chang JY, et al. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat 2009;19:321-56
   PubMed Web of Science ®Google Scholar
• Cheung CH, Coumar MS, Chang JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011;21:857-84
   PubMed Web of Science ®Google Scholar
• Kollareddy M, Zheleva D, Dzubak P, et al. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 2012;30:2411-32
   PubMed Web of Science ®Google Scholar
• Wissing MD, van Diest PJ, van der Wall E, et al. Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Expert Opin Investig Drugs 2013;22:635-61
   PubMed Web of Science ®Google Scholar
• Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011;155:561-79
   PubMed Web of Science ®Google Scholar
• Green MR, Woolery JE, Mahadevan D. Update on Aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 2011;6:291-307
   PubMed Web of Science ®Google Scholar
• Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013;27:113-17
   PubMed Web of Science ®Google Scholar
• Dewerth A, Wonner T, Lieber J, et al. In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma. Pediatr Surg Int 2012;28:579-89
   PubMedGoogle Scholar
• Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 2013;109:2607-18
   PubMed Web of Science ®Google Scholar
• Yao R, Zheng J, Zheng W, et al. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett 2014;7:121-4
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Carvajal RD, Midgley R, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2013;31:370-80
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 2013;119:2611-19
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, Bleuse JP, Vinci EM, et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2013;111:44-52
   PubMed Web of Science ®Google Scholar
• Fraedrich K, Schrader J, Ittrich H, et al. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clin Cancer Res 2012;18:4621-32
   PubMedGoogle Scholar
• Fei F, Lim M, Schmidhuber S, et al. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer 2012;11:42
   PubMed Web of Science ®Google Scholar
• Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011;6:e19164
   PubMed Web of Science ®Google Scholar
• Yang Y, Shen Y, Li S, et al. Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity. Mol Biosyst 2012;8:3049-60
   PubMedGoogle Scholar
• Palani S, Patel M, Huck J, et al. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 2013;72:1255-64
   PubMed Web of Science ®Google Scholar
• Kelly K, Shea T, Goy A, et al. Phase I study of MLN8237—investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 2014;32(3):489-99
   PubMed Web of Science ®Google Scholar
• Hrabakova R, Kollareddy M, Tyleckova J, et al. Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy. J Proteome Res 2013;12:455-69
   PubMedGoogle Scholar
• Baldini E, Sorrenti S, D’Armiento E, et al. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter 2012;163:e307-13
   PubMedGoogle Scholar
• Moy C, Oleykowski CA, Plant R, et al. High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916. J Transl Med 2011;9:110
   PubMedGoogle Scholar
• Schoffski P, Jones SF, Dumez H, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011;47:2256-64
   PubMed Web of Science ®Google Scholar
• Hook KE, Garza SJ, Lira ME, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012;11:710-19
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Lee J, Lasonde B, et al. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2013;49:121-31
   PubMed Web of Science ®Google Scholar
• Diamond JR, Eckhardt SG, Tan AC, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res 2013;19:291-303
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23:1307-13
   PubMed Web of Science ®Google Scholar
• Dent SF, Gelmon KA, Chi KN, et al. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs 2013;31:1522-9
   PubMed Web of Science ®Google Scholar
• Foran J, Ravandi F, Wierda W, et al. A phase I and pharmacodynamic Study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk 2014;14:223-30
   PubMed Web of Science ®Google Scholar
• Raymond E, Alexandre J, Faivre S, et al. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors. Invest New Drugs 2014;32:94-103
   PubMedGoogle Scholar
• Mita M, Gordon M, Rejeb N, et al. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Shan W, Akinfenwa PY, Savannah KB, et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 2012;18:3352-65
   PubMed Web of Science ®Google Scholar
• Horwacik I, Durbas M, Boratyn E, et al. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett 2013;341:248-64
   PubMed Web of Science ®Google Scholar
• Kalous O, Conklin D, Desai AJ, et al. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat 2013;141:397-408
   PubMed Web of Science ®Google Scholar
• Bush TL, Payton M, Heller S, et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol Cancer Ther 2013;12:2356-66
   PubMed Web of Science ®Google Scholar
• Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
   PubMed Web of Science ®Google Scholar
• Nguyen T, Dai Y, Attkisson E, et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2011;17:3219-32
   Google Scholar
• Ambit Biosciences Corp. Aurora kinase compounds and methods of their use. WO2011088045A1; 2011
   Google Scholar
• Amgen, Inc. N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer. WO2011031842A1; 2011
   Google Scholar
• Amgen, Inc. Aurora kinase modulators and method of use. WO07087276A1; 2007
   Google Scholar
• Payton M, Bush TL, Chung G, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70:9846-54
   PubMed Web of Science ®Google Scholar
• Huang L, Be X, Berry L, et al. In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases. Xenobiotica 2011;41:400-8
   PubMed Web of Science ®Google Scholar
• Boeringer Ingelheim International GMBH. Anticancer therapy with dual aurora kinase/MEK inhibitors. WO2012095505A1; 2012
   Google Scholar
• Boeringer Ingelheim International GMBH. New compounds. WO2010012747A1; 2010
   Google Scholar
• Boeringer Ingelheim International GMBH. Anticancer combination therapy. WO2013060872A1; 2013
   Google Scholar
• Cancer Research Technology Ltd. Pharmaceutically active compounds. WO2013190319A1; 2013
   Google Scholar
• Chroma Therapeutics Ltd. Enzyme inhibitors. WO07072017A2; 2007
   Google Scholar
• Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors. WO2009001021A1; 2009
   Google Scholar
• Cancer Research Technology Ltd. Imidazopyridines as inhibitors of aurora kinase and/or FLT3. WO2013190320A1; 2013
   Google Scholar
• Genosco and Oscotec, Inc. Kinase inhibitors. WO2011053861A1; 2011
   Google Scholar
• Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Preparation of 2,4-disubstituted thieno[3,2-d]pyrimidine compounds as anticancer agents. CN103242341A; 2013
   Google Scholar
• Merck GMBH. Novel bicyclic urea compounds. WO2011017142A1; 2011
   Google Scholar
• H. Lee Moffitt Cancer Centre and Research Institute. Aurora kinase inhibitors and methods of making and using thereof. WO2012135641A2; 2012
   Google Scholar
• Lawrence HR, Martin MP, Luo Y, et al. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. J Med Chem 2012;55:7392-416
   PubMedGoogle Scholar
• Nihon University. Selective expression inhibitor for aurora kinase A and aurora kinase B genes. WO2009066774A1; 2009
   Google Scholar
• National Health Research Institutes. Pyrazole compounds and thiazole compounds as protein kinase inhibitors. US20120225880A1; 2012
   Google Scholar
• Sanofi. Compound Ethyl 8-oxo-9-[3-[(1H-benzimidazol-2-yl)oxy]phenyl]-4,5,6,7,8,9-hexahydro-2H- pyrrolo[3,4-b]quinoline-3-carboxylate, salt, crystalline form, cocrystal, formulation, processes for preparation, application as medicaments, pharmaceutical compositions and new use particularly as inhibitors of Aurora kinases. WO2012066486A1; 2012
   Google Scholar
• Aventis Pharma S.A. 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them. WO07012972A2; 2007
   Google Scholar
• Sanofi-Aventis. Anticancer compounds and Phrmacuetical composition contatining the same. WO2010133794A1; 2010
   Google Scholar
• Shenzhen Salubris Pharmaceutical Co., Ltd. and Shanghai Institute of Pharmaceutical Industry. Polycyclic quinazolines, preparation thereof, and use thereof. US2011288086A1, WO2011144059A1; 2011
   Google Scholar
• Sun Yat Sen University. Preparation of pyrimidine derivatives as aurora kinase inhibitors for treatment of cancer. CN103059002A; 2013
   Google Scholar
• Sun Yat Sen University. Application of pyrimidine derivative in preparing drug for prevention, treatment, and/or adjuvant treatment of tumor. CN103191120A; 2013
   Google Scholar
• Sun Yat Sen University. Application of pyrimidine derivative in preparing drugs for prevention/treatment/auxiliary treatment of cancer. CN103202843A; 2013
   Google Scholar
• Sunshine Lake Pharma Co., Ltd. Substitued pyrimidine derivatives as aurora kinase inhibitor. WO2013143466A1; 2013
   Google Scholar
• Feng Y, Chen YT, Sessions H, et al. Bicyclic heteroaryls as kinase inhibitors. WO2011050245A1; 2011
   Google Scholar
• Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012;18:51-63
   PubMed Web of Science ®Google Scholar
• Bearss DJ. Shining the light on aurora-a kinase as a drug target in pancreatic cancer. Mol Cancer Ther 2011;10:2012
   PubMedGoogle Scholar
• Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15:6694-701
   PubMed Web of Science ®Google Scholar
• US clinical trials database Available from: www.clinicaltrials.gov
   Google Scholar